The genetic activity of anthramycin, tomaymycin and sibiromycin in bacterial forward‐ and reverse‐mutation assays and in the mouse bone‐marrow micronucleus test

C. Gairola, H. Thomas, S. L. Szeinbach, William Charles Lubawy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The genetic activity of the structurally similar antitumor antibiotics anthramycin, tomaymycin and sibiromycin was evaluated in the standard Ames Salmonella/microsome mutagenicity assay, a Salmonella typhimurium forward‐mutation assay and the micronucleus test. None of the test drugs showed any significant genetic activity in forward or reverse Salmonella mutation assays. The ability of mouse‐liver enzymes to produce mutagens from the drugs was examined in the Salmonella reverse‐mutation assay and was generally negative. As the concentrations of sibiromycin increased, some activity was detected in the presence of liver S‐9 fractions from Aroclor‐induced mice. This observation could not be verified at higher concentrations in the reverse‐mutation assay due to cytotoxicity, and in the forward‐mutation assay due to interference with the selection process by S‐9. Cytogenetic evaluation of anthramycin and tomaymycin in the micronucleus test also gave negative results. However, significant increases in the frequency of micronucleated polychromatic erythrocytes were observed in the bone marrow of sibiromycin‐treated mice. The results suggest that, except for some possible activity of sibiromycin, these drugs are generally devoid of any marked genetic activity in the test systems employed.

Original languageEnglish
Pages (from-to)317-320
Number of pages4
JournalJournal of Applied Toxicology
Volume3
Issue number6
DOIs
StatePublished - 1 Jan 1983

Fingerprint

Anthramycin
Micronucleus Tests
Salmonella
Assays
Pharmaceutical Preparations
Mutagens
Salmonella typhimurium
Microsomes
Cytogenetics
Erythrocytes
Bone Marrow
Anti-Bacterial Agents
Mutation
Liver
Enzymes
Cytotoxicity
tomaymycin
sibiromycin
Bone

Keywords

  • anthramycin
  • anticancer drugs
  • mutation assays
  • sibiromycin
  • tomaymycin

Cite this

@article{4d41c5ffe6f34967933b8a77129e59e8,
title = "The genetic activity of anthramycin, tomaymycin and sibiromycin in bacterial forward‐ and reverse‐mutation assays and in the mouse bone‐marrow micronucleus test",
abstract = "The genetic activity of the structurally similar antitumor antibiotics anthramycin, tomaymycin and sibiromycin was evaluated in the standard Ames Salmonella/microsome mutagenicity assay, a Salmonella typhimurium forward‐mutation assay and the micronucleus test. None of the test drugs showed any significant genetic activity in forward or reverse Salmonella mutation assays. The ability of mouse‐liver enzymes to produce mutagens from the drugs was examined in the Salmonella reverse‐mutation assay and was generally negative. As the concentrations of sibiromycin increased, some activity was detected in the presence of liver S‐9 fractions from Aroclor‐induced mice. This observation could not be verified at higher concentrations in the reverse‐mutation assay due to cytotoxicity, and in the forward‐mutation assay due to interference with the selection process by S‐9. Cytogenetic evaluation of anthramycin and tomaymycin in the micronucleus test also gave negative results. However, significant increases in the frequency of micronucleated polychromatic erythrocytes were observed in the bone marrow of sibiromycin‐treated mice. The results suggest that, except for some possible activity of sibiromycin, these drugs are generally devoid of any marked genetic activity in the test systems employed.",
keywords = "anthramycin, anticancer drugs, mutation assays, sibiromycin, tomaymycin",
author = "C. Gairola and H. Thomas and Szeinbach, {S. L.} and Lubawy, {William Charles}",
year = "1983",
month = "1",
day = "1",
doi = "10.1002/jat.2550030609",
language = "English",
volume = "3",
pages = "317--320",
journal = "Journal of Applied Toxicology",
issn = "0260-437X",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

The genetic activity of anthramycin, tomaymycin and sibiromycin in bacterial forward‐ and reverse‐mutation assays and in the mouse bone‐marrow micronucleus test. / Gairola, C.; Thomas, H.; Szeinbach, S. L.; Lubawy, William Charles.

In: Journal of Applied Toxicology, Vol. 3, No. 6, 01.01.1983, p. 317-320.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The genetic activity of anthramycin, tomaymycin and sibiromycin in bacterial forward‐ and reverse‐mutation assays and in the mouse bone‐marrow micronucleus test

AU - Gairola, C.

AU - Thomas, H.

AU - Szeinbach, S. L.

AU - Lubawy, William Charles

PY - 1983/1/1

Y1 - 1983/1/1

N2 - The genetic activity of the structurally similar antitumor antibiotics anthramycin, tomaymycin and sibiromycin was evaluated in the standard Ames Salmonella/microsome mutagenicity assay, a Salmonella typhimurium forward‐mutation assay and the micronucleus test. None of the test drugs showed any significant genetic activity in forward or reverse Salmonella mutation assays. The ability of mouse‐liver enzymes to produce mutagens from the drugs was examined in the Salmonella reverse‐mutation assay and was generally negative. As the concentrations of sibiromycin increased, some activity was detected in the presence of liver S‐9 fractions from Aroclor‐induced mice. This observation could not be verified at higher concentrations in the reverse‐mutation assay due to cytotoxicity, and in the forward‐mutation assay due to interference with the selection process by S‐9. Cytogenetic evaluation of anthramycin and tomaymycin in the micronucleus test also gave negative results. However, significant increases in the frequency of micronucleated polychromatic erythrocytes were observed in the bone marrow of sibiromycin‐treated mice. The results suggest that, except for some possible activity of sibiromycin, these drugs are generally devoid of any marked genetic activity in the test systems employed.

AB - The genetic activity of the structurally similar antitumor antibiotics anthramycin, tomaymycin and sibiromycin was evaluated in the standard Ames Salmonella/microsome mutagenicity assay, a Salmonella typhimurium forward‐mutation assay and the micronucleus test. None of the test drugs showed any significant genetic activity in forward or reverse Salmonella mutation assays. The ability of mouse‐liver enzymes to produce mutagens from the drugs was examined in the Salmonella reverse‐mutation assay and was generally negative. As the concentrations of sibiromycin increased, some activity was detected in the presence of liver S‐9 fractions from Aroclor‐induced mice. This observation could not be verified at higher concentrations in the reverse‐mutation assay due to cytotoxicity, and in the forward‐mutation assay due to interference with the selection process by S‐9. Cytogenetic evaluation of anthramycin and tomaymycin in the micronucleus test also gave negative results. However, significant increases in the frequency of micronucleated polychromatic erythrocytes were observed in the bone marrow of sibiromycin‐treated mice. The results suggest that, except for some possible activity of sibiromycin, these drugs are generally devoid of any marked genetic activity in the test systems employed.

KW - anthramycin

KW - anticancer drugs

KW - mutation assays

KW - sibiromycin

KW - tomaymycin

UR - http://www.scopus.com/inward/record.url?scp=0020958194&partnerID=8YFLogxK

U2 - 10.1002/jat.2550030609

DO - 10.1002/jat.2550030609

M3 - Article

C2 - 6376603

AN - SCOPUS:0020958194

VL - 3

SP - 317

EP - 320

JO - Journal of Applied Toxicology

JF - Journal of Applied Toxicology

SN - 0260-437X

IS - 6

ER -